References

Leverage extensive methylation coverage for multiple precision oncology applications.¹

Increase accuracy in MRD and monitoring through enhanced ctDNA detection and quantification.¹

Increased Sensitivity

Identify new patients or predict response to therapy through novel epigenomic biomarkers.2-4

ctDNA, circulating tumor DNA; MRD, minimal residual disease.

Promoter Methylation

Methylation Signatures